A new review in Virology Journal examines how siRNA and CRISPR/Cas gene-silencing technologies could target the HPV16 ...

Anthropic’s claim its AI agents discovered an unusual pattern in viral DNA similar to what’s seen in the gene-editing tool ...

IntroductionCRISPR-Cas has fundamentally transformed the landscape of genetic manipulation in life sciences. This technology, which recognizes, cuts, and edits specific DNA sequences, is utilized in a ...

CRISPR-Cas13 has rapidly become one of the most versatile tools in plant biotechnology, offering researchers the ability to ...

Experts at the company don't know what the newfound system does, so its potential utility in biology—if any—remains unclear.

Beam Therapeutics is reaffirmed as a long-term buy, with significant upside expected around 2028–2029 as BEAM-302 advances.

A groundbreaking Phase 1 clinical trial conducted by Cleveland Clinic has unveiled promising results regarding a novel CRISPR ...

On September 23, 2026, Anthropic announced that "Claude discovered a previously unknown enzyme mechanism within viral DNA" ...

Anthropic’s Claude Mythos 5 agents autonomously searched 1.9 billion protein clusters and identified ART, a previously uncharacterized enzyme system in bacteriophage DNA with CRISPR-like structural ...

Anthropic said on Wednesday that its signature AI model, Claude, had “autonomously” discovered the system at the prompting of researchers working at the company’s recently established biology research ...